Imaging and Biomarker Core

成像和生物标志物核心

• 批准号: 10661547
• 负责人: Thomas J. Grabowski
• 金额: $ 23.17万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-01 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10661547
• 关键词: Abbreviations; Alaska Native; Alzheimer' s Disease; Alzheimer' s disease related dementia; American Indians; Anatomy; Architecture; Archives; Automobile Driving; Autopsy; Biological Markers; Blood; Brain; Brain region; Cerebral cortex; Characteristics; Classification; Clinic; Clinical; Cognition; Cognitive; Data; Data Analyses; Data Science; Data Set; Dementia; Dimensions; Enrollment; Ensure; Foundations; Funding; Genetic; Goals; Heterogeneity; Image; Image Analysis; Impaired cognition; Informatics; Letters; Link; Liquid substance; MRI Scans; Machine Learning; Magnetic Resonance Imaging; Maps; Measures; Memory; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; Nerve Degeneration; Participant; Pathologic; Pattern; Phenotype; Positron-Emission Tomography; Process; Quality Control; Research; Research Personnel; Resources; Sampling; Source; Specificity; Structure; Tissue Sample; Universities; Washington; Wellness Center; biological heterogeneity; cell repository; central database; cohort; data management; education research; human subject; imaging study; in vivo; medical schools; molecular imaging; multidisciplinary; neuroimaging; neuropathology; novel; outreach; phenotypic data; recruit; repository; resilience; statistics

Abstract The Imaging and Biomarker (IB) Core will characterize participants in the Clinical Core through neuroimaging and fluid biomarker analysis, in conformity with prevailing standards. A further focus is to rigorously describe topographic phenotypes of the participants and to link this information to cognitive, fluid biomarker, genetic, and neuropathologic data generated by the Center. The Core will also provide an information architecture and consulting expertise to represent the imaging data to ADRC-affiliated studies and investigators. Many UW ADRC-affiliated studies require human subjects who are well-characterized with imaging and fluid biomarkers. MRI imaging will be obtained on all normal cognition, MCI, and mild AD participants in the Clinical and Native Research and Resource (NRRC) Cores. We will characterize our Clinical Core cohort with A|T|N classification, primarily with CSF biomarkers (A, T) and MRI (N) imaging. The IB Core will coordinate PET scans in ADRC affiliate projects or co-enroll affiliate subjects in the Clinical Core to ensure Clinical Core subjects have PET scanning performed. We provide expertise in planning and analyzing PET molecular imaging studies. Affiliated studies are investigating specific candidate mechanisms of AD, as well as whether, and why, different pathological mechanisms inherent in AD have differing patterns of impact over the cerebral cortex. For such studies, the brain space is a point of integration of the other biomarkers of AD. We have organized the IB Core and its interactions with the Clinical and Neuropathology Cores such that topographical heterogeneity, determined from imaging data, is incorporated as a phenotypic characteristic, along with cognitive domain, fluid biomarker, and genetic data. We will measure cortical degeneration, as well as cortical sparing, across a set of brain regions that represent the range and variability of involvement in AD. Another important aspect of cognitive variability is the relationship of the degree of cognitive impairment that results from a given degree of neurodegeneration (cognitive resilience). Thus we will also extract measures of cognitive resilience from cognitive and anatomic data, as another phenotypic dimension. We will provide consulting expertise in informatics/machine learning, image analysis and statistics for the description and analysis of these data. We have also structured the Core to support the same multidisciplinary phenotyping in decedents from the Clinical cohort who come to autopsy. We will perform ex vivo MRI in all, and process structural measures as in the in vivo studies. We will sample tissue from the same regions that we target with imaging in living participants. We will calculate analogous resilience measures. Ex vivo MRI will also enable targeted sampling of MRI-apparent abnormalities at autopsy and mapping neuropathologic data into standard anatomical space.

抽象的 影像和生物标志物 (IB) 核心将通过神经影像来描述临床核心参与者的特征 和液体生物标志物分析，符合现行标准。进一步的重点是严格描述 参与者的地形表型，并将这些信息与认知、液体生物标志物、遗传、 和中心生成的神经病理学数据。该核心还将提供信息架构和 咨询专业知识，向 ADRC 附属研究和调查人员展示成像数据。 华盛顿大学 ADRC 附属的许多研究都需要具有良好成像和特征的人类受试者。 液体生物标志物。将对所有正常认知、MCI 和轻度 AD 参与者进行 MRI 成像 临床和本土研究与资源 (NRRC) 核心。我们将描述我们的临床核心队列 A|T|N 分类，主要采用脑脊液生物标志物（A、T）和 MRI（N）成像。 IB核心将协调 ADRC 附属项目中的 PET 扫描或在临床核心中共同注册附属受试者以确保临床核心 受试者接受 PET 扫描。我们提供规划和分析 PET 分子的专业知识 影像学研究。 附属研究正​​在调查 AD 的具体候选机制，以及是否以及为什么， AD 固有的不同病理机制对大脑皮层有不同的影响模式。为了 此类研究表明，大脑空间是AD其他生物标志物的整合点。我们组织了IB 核心及其与临床和神经病理学核心的相互作用，使得地形异质性， 根据成像数据确定，与认知域、流体一起作为表型特征并入 生物标志物和遗传数据。我们将测量一组中的皮质变性以及皮质保留情况 代表 AD 参与范围和变异性的大脑区域。另一个重要方面 认知变异性是由给定程度的认知障碍引起的认知障碍程度之间的关系。 神经退行性变（认知弹性）。因此，我们还将从中提取认知弹性的衡量标准 认知和解剖数据，作为另一个表型维度。我们将提供咨询专业知识 用于描述和分析这些数据的信息学/机器学习、图像分析和统计。 我们还构建了核心，以支持死者的相同多学科表型 前来尸检的临床队列。我们将全部进行离体MRI，并进行结构测量 正如体内研究一样。我们将从活体成像所针对的相同区域采集组织样本 参与者。我们将计算类似的弹性措施。离体 MRI 还将实现定向采样 尸检时 MRI 明显异常的情况，并将神经病理学数据映射到标准解剖空间中。